As the push continues to create a vaccination for COVID-19, Morehouse School of Medicine (MSM) is conducting two novel coronavirus-related clinical trials.
As MSM’s clinical trials are happening locally, Pfizer and Moderna recently announced promising results from their Phase 3 trials. According to Pfizer, their vaccine appears to be more than 90% effective and Moderna’s vaccine appears to be 94.5% effective.
Lilly Immergluck, an associate professor of microbiology, biochemistry, immunology and pediatrics and the director of the Pediatric Clinical & Translational Research Unit, Clinical Research Center, joined Monday’s edition of “Closer Look.”
Immergluck talked with show host Rose Scott about combating the global health crisis, COVID-19 testing and the phases of MSM’s clinical trials.
To listen to the full conversation, click the audio player above.
